We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Opiod Patch for Pediatric Patients

By HospiMedica staff writers
Posted on 24 Nov 2005
A transdermal patch that delivers the opiod fentanyl to control pain has been found safe for use by children aged two to 16 years, according to a study in the December 15, 2005, issue of Cancer.

Very little is known about pain experience and the safety and efficacy of opoids in children. More...
At one time, children were thought to have a higher risk addiction than adults. New findings show that they are no more at risk than adults, but may not easily accept an injection or pill for pain.

Researchers from the Children's National Medical Center (Washington, DC, USA) and international colleagues examined 173 children, aged two to16 years. Many were cancer patients or had a history of chronic pain and prior opiod use. They were transitioned to the use of the fentanyl patch, adjusted to equal the concentration in their previous doses, and followed for 15 days.

The study found that subjective pain and the quality of life of the children improved. By day 16, the average daily pain intensity score decreased. After one month, quality-of-life scores increased; and after three months, average play performance scores also improved. There were no more adverse experiences than reported by adults and none specific for the pediatric population.

"Results from global measurements of pain treatment, safety, and quality of life indicate that transdermal fentanyl is an acceptable alternative to oral opiod therapy in children,” wrote the authors. An opioid patch, such as fentanyl, "is especially useful for good pain management in children with life-threatening conditions in which oral or injectable routes of drug delivery are difficult to administer or add further distress.”




Related Links:
Children's National Med. Center

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
Radiation Safety Barrier
RayShield Intensi-Barrier
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.